WO1998040356A1
(en)
*
|
1997-03-12 |
1998-09-17 |
Banyu Pharmaceutical Co., Ltd. |
Drugs containing aminopyridine derivatives as the active ingredient
|
GB9709815D0
(en)
*
|
1997-05-14 |
1997-07-09 |
Merck Sharp & Dohme |
Therapeutic method
|
WO1999001128A1
(en)
|
1997-07-03 |
1999-01-14 |
Neurogen Corporation |
Certain diarylimidazole derivatives; a new class of npy specific ligands
|
CA2301821A1
(en)
*
|
1997-08-25 |
1999-03-04 |
Bayer Corporation |
Heterocyclic ketones as npy y5 antagonists
|
WO1999027965A1
(en)
*
|
1997-11-28 |
1999-06-10 |
Banyu Pharmaceutical Co., Ltd. |
Antihyperlipemic agents
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
TR200100137T2
(en)
*
|
1998-04-29 |
2001-05-21 |
Ortho-Mcneil Pharmaceutical, Inc. |
N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
|
DE69929235T2
(en)
|
1998-11-10 |
2006-08-24 |
Merck & Co., Inc. |
SPIRO INDOLE AS Y5 RECEPTOR ANTAGONISTS
|
US6407120B1
(en)
|
1999-02-18 |
2002-06-18 |
Pfizer Inc. |
Neuropeptide Y antagonists
|
AU3840000A
(en)
|
1999-04-20 |
2000-11-02 |
Meiji Seika Kaisha Ltd. |
Tricyclic compounds
|
US6218408B1
(en)
|
1999-06-30 |
2001-04-17 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (bicyclics)
|
US6340683B1
(en)
|
1999-04-22 |
2002-01-22 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (triazines)
|
CA2371274A1
(en)
|
1999-04-22 |
2000-11-02 |
Synaptic Pharmaceutical Corporation |
Selective npy (y5) antagonists
|
US6989379B1
(en)
|
1999-04-22 |
2006-01-24 |
H. Lundbick A/S |
Selective NPY (Y5) antagonists
|
US6841552B1
(en)
|
1999-05-05 |
2005-01-11 |
Ortho-Mcneil Pharmaceutical, Inc. |
3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
|
CA2373035A1
(en)
*
|
1999-05-05 |
2000-11-16 |
Scott Dax |
3a,4,5,9b-tetrahydro-1h-benz[e]indol-2-yl amine-derived neuropeptide y receptors ligands useful in the treatment of obesity and other disorders
|
US7273880B2
(en)
|
1999-06-30 |
2007-09-25 |
H. Lunbeck A/S |
Selective NPY (Y5) antagonists
|
US6225330B1
(en)
|
1999-06-30 |
2001-05-01 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (tricyclics)
|
US6222040B1
(en)
|
1999-06-30 |
2001-04-24 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (tricyclics)
|
US6214853B1
(en)
|
1999-06-30 |
2001-04-10 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (bicyclics)
|
JP2003512349A
(en)
|
1999-10-15 |
2003-04-02 |
デュポン ファーマシューティカルズ カンパニー |
Benzylcycloalkylamines as modulators of chemokine receptor activity
|
US6291499B1
(en)
*
|
1999-10-29 |
2001-09-18 |
Merck & Co., Inc. |
2-cyclohexyl benzimidazole NMDA/NR2B antagonists
|
ATE405257T1
(en)
|
1999-11-26 |
2008-09-15 |
Shionogi & Co |
NPYY5 ANTAGONISTS
|
SK632003A3
(en)
|
2000-07-13 |
2003-06-03 |
Lilly Co Eli |
Beta3 adrenergic agonists
|
KR20040058191A
(en)
*
|
2001-10-01 |
2004-07-03 |
다이쇼 세이야꾸 가부시끼가이샤 |
MCH Receptor Antagonists
|
CA2403307A1
(en)
*
|
2001-10-23 |
2003-04-23 |
Neurogen Corporation |
Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
|
ES2193875B2
(en)
|
2002-04-09 |
2005-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
EP1398032A1
(en)
*
|
2002-09-10 |
2004-03-17 |
PheneX Pharmaceuticals AG |
4-Oxo-quinazolines as LXR nuclear receptor binding compounds
|
EP1407774A1
(en)
*
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
US7589207B2
(en)
|
2002-12-13 |
2009-09-15 |
Smithkline Beecham Corporation |
Cyclohexyl compounds as CCR5 antagonists
|
CA2513086A1
(en)
*
|
2002-12-19 |
2004-07-08 |
Scios Inc. |
Treatment of obesity and associated conditions with tgf-.beta. inhibitors
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP2004315511A
(en)
*
|
2003-03-31 |
2004-11-11 |
Taisho Pharmaceut Co Ltd |
Mch receptor antagonist
|
EP1611109A4
(en)
*
|
2003-03-31 |
2009-06-24 |
Taisho Pharmaceutical Co Ltd |
Novel quinazoline derivatives and methods of treatment related to the use thereof
|
ATE462432T1
(en)
|
2003-05-05 |
2010-04-15 |
Probiodrug Ag |
GLUTAMINYL CYCLASE INHIBITORS
|
ATE440825T1
(en)
|
2003-06-06 |
2009-09-15 |
Vertex Pharma |
PYRIMIDINE DERIVATIVES FOR USE AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
ES2222833B1
(en)
|
2003-07-30 |
2006-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
1,4-DISPOSED PIPERIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
|
AU2004274309B2
(en)
|
2003-09-22 |
2010-04-08 |
Msd K.K. |
Novel piperidine derivative
|
EP1723126A2
(en)
|
2003-10-22 |
2006-11-22 |
Eli Lilly And Company |
Novel mch receptor antagonists
|
AU2004290499C1
(en)
|
2003-11-03 |
2011-02-24 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
GB0400193D0
(en)
*
|
2004-01-07 |
2004-02-11 |
Astrazeneca Ab |
Therapeutic agents
|
BRPI0507485A
(en)
|
2004-02-05 |
2007-07-10 |
Probiodrug Ag |
new glutaminyl cyclase inhibitors
|
NZ549673A
(en)
*
|
2004-03-30 |
2010-03-26 |
Taisho Pharmaceutical Co Ltd |
Pyrimidine derivatives and methods of treatment related to the use thereof
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
Method of treating men with metabolic and anthropometric disorders
|
US7601714B2
(en)
*
|
2004-07-08 |
2009-10-13 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pyrimidine derivatives useful as inhibitors of PKC-theta
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP2127676A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and related disorders
|
CA2592900A1
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US8138206B2
(en)
|
2005-05-30 |
2012-03-20 |
Msd. K.K. |
Piperidine derivative
|
US20060281712A1
(en)
|
2005-06-14 |
2006-12-14 |
Chi-Feng Yen |
Pyrimidine compounds
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
EP1922336B1
(en)
|
2005-08-11 |
2012-11-21 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
DE602006017712D1
(en)
|
2005-08-24 |
2010-12-02 |
Banyu Pharma Co Ltd |
PHENYLPYRIDONDERIVAT
|
WO2007029847A1
(en)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
Bicyclic aromatic substituted pyridone derivative
|
BRPI0616463A2
(en)
|
2005-09-29 |
2011-06-21 |
Merck & Co Inc |
compound, pharmaceutical composition, and use of a compound
|
BRPI0617621A2
(en)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combination of organic compounds
|
JPWO2007049798A1
(en)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
New benzooxathiin derivatives
|
KR101318127B1
(en)
|
2005-11-10 |
2013-10-16 |
엠에스디 가부시키가이샤 |
Aza-substituted spiro derivative
|
JP4528901B2
(en)
|
2006-04-28 |
2010-08-25 |
塩野義製薬株式会社 |
Amine derivatives having NPYY5 receptor antagonistic activity
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20090247560A1
(en)
|
2006-09-28 |
2009-10-01 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
EP2089383B1
(en)
|
2006-11-09 |
2015-09-16 |
Probiodrug AG |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
JP5523107B2
(en)
|
2006-11-30 |
2014-06-18 |
プロビオドルグ エージー |
Novel inhibitors of glutaminyl cyclase
|
ZA200905537B
(en)
|
2007-03-01 |
2010-10-27 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
CA2682727C
(en)
|
2007-04-02 |
2016-03-22 |
Banyu Pharmaceutical Co., Ltd. |
Indoledione derivative
|
ES2533484T3
(en)
|
2007-04-18 |
2015-04-10 |
Probiodrug Ag |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MX354786B
(en)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
|
SA08290668B1
(en)
|
2007-10-25 |
2012-02-12 |
شيونوجي آند كو.، ليمتد |
Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
|
PE20091309A1
(en)
*
|
2007-12-21 |
2009-09-30 |
Astrazeneca Ab |
CYCLOHEXYL DERIVATIVES AS ACETYL COENZYME CARBOXYLASE INHIBITORS
|
US20110015181A1
(en)
|
2008-03-06 |
2011-01-20 |
Makoto Ando |
Alkylaminopyridine derivative
|
WO2009119726A1
(en)
|
2008-03-28 |
2009-10-01 |
萬有製薬株式会社 |
Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
|
AU2008355098B2
(en)
|
2008-04-21 |
2012-11-15 |
Gpcr Therapeutics, Inc |
Heterocyclic compounds
|
CL2009000904A1
(en)
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
|
ES2627848T3
(en)
|
2008-06-04 |
2017-07-31 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
AU2009261248A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
ES2624828T3
(en)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
PE20110852A1
(en)
|
2008-10-30 |
2011-11-25 |
Merck Sharp & Dohme |
ISONICOTINAMIDE OREXIN RECEPTOR ANTAGONISTS
|
AU2009309037A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
TW201021855A
(en)
|
2008-11-13 |
2010-06-16 |
Taigen Biotechnology Co Ltd |
Lyophilization formulation
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
WO2010075069A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Bicyclic pyranone derivatives as nicotinic acid receptor agonists
|
EP2404896A1
(en)
|
2009-03-05 |
2012-01-11 |
Shionogi&Co., Ltd. |
Cyclohexane derivative having npy y5 receptor antagonism
|
US8227618B2
(en)
|
2009-04-23 |
2012-07-24 |
Shionogi & Co., Ltd. |
Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
|
EP2473487B1
(en)
*
|
2009-09-03 |
2016-10-26 |
Bristol-Myers Squibb Company |
Quinazolines as potassium ion channel inhibitors
|
DK2475428T3
(en)
|
2009-09-11 |
2015-09-28 |
Probiodrug Ag |
Heterocyclic derivatives as glutaminylcyklaseinhibitorer
|
CA2786314A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
CN102791704B
(en)
|
2010-03-10 |
2015-11-25 |
前体生物药物股份公司 |
The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
|
JP5945532B2
(en)
|
2010-04-21 |
2016-07-05 |
プロビオドルグ エージー |
Benzimidazole derivatives as inhibitors of glutaminyl cyclase
|
US8748433B2
(en)
|
2010-04-30 |
2014-06-10 |
Merck Sharp & Dohme Corp. |
β3 adrenergic receptor agonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
MY159058A
(en)
|
2011-02-25 |
2016-12-15 |
Merck Sharp & Dohme |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent
|
ES2570167T3
(en)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Benzimidazole derivatives as glutaminyl cyclase inhibitors
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
RU2015106909A
(en)
|
2012-08-02 |
2016-09-27 |
Мерк Шарп И Доум Корп. |
ANTI-DIABETIC TRICYCLIC COMPOUNDS
|
US9840512B2
(en)
|
2013-02-22 |
2017-12-12 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
KR102272746B1
(en)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CA2959208C
(en)
|
2014-08-29 |
2023-09-19 |
Tes Pharma S.R.L. |
Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase
|
MX2019004321A
(en)
|
2016-10-14 |
2019-06-12 |
Tes Pharma S R L |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase.
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
EP3461819B1
(en)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
CN113302189A
(en)
|
2018-11-20 |
2021-08-24 |
Tes制药有限责任公司 |
Inhibitors of alpha-amino-beta-carboxyadipimic acid semialdehyde decarboxylating enzyme
|
AU2019387370A1
(en)
|
2018-11-30 |
2021-06-10 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
EP3924058A1
(en)
|
2019-02-13 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
MX2022000492A
(en)
|
2019-07-11 |
2022-07-04 |
Praxis Prec Medicines Inc |
Formulations of t-type calcium channel modulators and methods of use thereof.
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
CN116249697A
(en)
|
2020-08-18 |
2023-06-09 |
默沙东有限责任公司 |
Bicycloheptane pyrrolidine orexin receptor agonists
|
CN114315802B
(en)
*
|
2021-12-14 |
2023-06-16 |
西安医学院 |
Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application
|
KR20230098496A
(en)
*
|
2021-12-24 |
2023-07-04 |
아주대학교산학협력단 |
Novel compound for improving sleep and uses thereof
|